Are measures and related symptoms of cachexia recorded as outcomes in gastrointestinal cancer chemotherapy clinical trials? DOI Creative Commons
Ross Valaire, Frances L. Garden, Valentina Razmovski‐Naumovski

и другие.

Journal of Cachexia Sarcopenia and Muscle, Год журнала: 2024, Номер 15(3), С. 1146 - 1156

Опубликована: Март 27, 2024

Cachexia is prevalent in gastrointestinal cancers and worsens patient outcomes chemotherapy compliance. We examined to what extent registered cancer clinical trials record measures related symptoms of cachexia as outcomes, whether these were associated with trial characteristics.

Язык: Английский

Prevalence and survival implications of malnutrition and sarcopenia in metastatic breast cancer: A longitudinal analysis DOI Creative Commons

Géraldine M. Camilleri,

Lidia Delrieu, Carole Bouleuc

и другие.

Clinical Nutrition, Год журнала: 2024, Номер 43(8), С. 1710 - 1718

Опубликована: Июнь 14, 2024

Malnutrition and sarcopenia are challenges for patients with metastatic breast cancer have been proposed as independent prognostic factors. Very few studies addressed the temporal evolution of these parameters and, notably, separate combined analysis malnutrition. This study aimed to i) determine prevalence malnutrition sarcopenia, individually combined, their over time, ii) identify risk factors each condition, iii) explore impact on overall survival (OS).

Язык: Английский

Процитировано

3

Effect on an Oral Nutritional Supplement with β-Hydroxy-β-methylbutyrate and Vitamin D on Morphofunctional Aspects, Body Composition, and Phase Angle in Malnourished Patients DOI Open Access
Isabel Cornejo‐Pareja, Marı́a Jesús Ramı́rez-Expósito,

María Camprubí-Robles

и другие.

Nutrients, Год журнала: 2021, Номер 13(12), С. 4355 - 4355

Опубликована: Дек. 3, 2021

This is a retrospective study of data from clinical practice to observe the effect high-calorie, high-protein oral nutritional supplement (ONS) with β-hydroxy-β-methylbutyrate (HMB) on status, body weight, and muscle-related parameters in 283 adult patients or at risk malnutrition under standard care, 63% being cancer patients. They were recommended increase physical activity energy protein intake regular diet plus two servings per day specialized ONS enriched HMB for up 6 months. Dietary records, adherence tolerance ONS, composition, handgrip strength, blood analysis beginning end intervention recorded. program improved status 100% malnourished baseline 80% well-nourished final visit. It also increased weight by 3.6-3.8 kg, fat-free mass 0.9 1.3 strength 4.7 6.2 kg. In subgroup (n = 43), phase angle (PhA), cell (BCM) only receiving (0.95 (0.13) vs. -0.36 (0.4), 2.98 (0.5) -0.6 (1.5) mean difference (SE) PhA BCM, respectively), suggesting potential efficacy this muscle health.

Язык: Английский

Процитировано

20

Neuroendocrine Tumors: A Comprehensive Review on Nutritional Approaches DOI Open Access
Giovanna Muscogiuri, Luigi Barrea, Maria Celeste Cantone

и другие.

Cancers, Год журнала: 2022, Номер 14(18), С. 4402 - 4402

Опубликована: Сен. 10, 2022

Neuroendocrine neoplasms are a heterogeneous group of with increasing incidence, high prevalence, and survival worldwide. About 90% cases well differentiated forms, the so-called neuroendocrine tumors (NETs), slow proliferation rates prolonged but frequent development liver metastases endocrine syndromes. Both tumor itself systemic therapy may have an impact on patient nutrition. Malnutrition has negative outcome in patients NETs, as obesity. In addition, obesity metabolic syndrome been shown to be risk factors for both prognosis NET. Therefore, dietary assessment based body composition lifestyle modifications should integral part treatment NET patients. Nutrition plans, properly formulated by dietician, multidisciplinary team NETs because they allow improvement quality life, providing tailored approach nutritional needs manageable signs and/or symptoms related pharmacological treatment. The aim this review is condense latest evidence role most used models, Mediterranean diet, ketogenic intermittent fasting, context while considering clinical molecular mechanisms which these models act.

Язык: Английский

Процитировано

14

Relevance of Dietary Supplement Use in Gastrointestinal-Cancer-Associated Cachexia DOI Open Access
Saunjoo L. Yoon, Oliver Grundmann

Nutrients, Год журнала: 2023, Номер 15(15), С. 3391 - 3391

Опубликована: Июль 30, 2023

Cancer cachexia is a multi-organ syndrome with unintentional weight loss, sarcopenia, and systemic inflammation. Gastrointestinal (GI) cancer patients are more susceptible to development due impaired nutrient absorption digestion. Given the widespread availability relatively low cost of dietary supplements, we examined evidence effects fish oil (omega-3 fatty acids), melatonin, probiotics, green tea for managing symptoms GI cachexia. A literature review four specific supplements was conducted using PubMed, Google Scholar, CINAHL without date restriction. Of 4621 available references, 26 articles were eligible review. Fish decreased C-reactive protein maintained CD4+ cell count, while melatonin indicated inconsistent findings on cachexia, but well-tolerated. Probiotics serum pro-inflammatory biomarkers increased tolerability chemotherapy by reducing side effects. Green preparations extracts showed risk developing various cancers did not impact tumor growth, survival, or adverse Among these probiotics most promising further research in preventing inflammation maintaining adequate nutrients prevent progression Supplements may benefit treatment outcomes supporting nutritional therapeutic needs.

Язык: Английский

Процитировано

7

Are measures and related symptoms of cachexia recorded as outcomes in gastrointestinal cancer chemotherapy clinical trials? DOI Creative Commons
Ross Valaire, Frances L. Garden, Valentina Razmovski‐Naumovski

и другие.

Journal of Cachexia Sarcopenia and Muscle, Год журнала: 2024, Номер 15(3), С. 1146 - 1156

Опубликована: Март 27, 2024

Cachexia is prevalent in gastrointestinal cancers and worsens patient outcomes chemotherapy compliance. We examined to what extent registered cancer clinical trials record measures related symptoms of cachexia as outcomes, whether these were associated with trial characteristics.

Язык: Английский

Процитировано

2